Adenovirus Vaccines

Adenovirus Infections

Parathyroid Hormone PTH Receptor

There are two known parathyroid hormone receptors in mammals termed PTH1R and PTH2R. These receptors bind parathyroid hormone and are members of the GPCR family of transmembrane proteins. * parathy...

Multiple Sclerosis MS

Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference i...

CD30 Antibodies

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. This receptor is expressed by activated, but not by resting, T and B cells. It...

ORCA granted Chinese Patent for oncolytic adenovirus technology

March 20, 2013 – ORCA Therapeutics, a pioneer in the development of innovative virotherapies for treatment of cancer, has secured key intellectual property rights for its T1 oncolytic adenovirus tec...

ORCA granted Chinese Patent covering T1 oncolytic adenovirus technology

March 20, 2013 – ORCA Therapeutics, a pioneer in the development of innovative virotherapies for treatment of cancer, has secured key intellectual property rights for its T1 oncolytic adenovirus tec...

Infectivity-selective Oncolytic Adenovirus Developed by High-throughput Screening of Adenovirus-formatted Library

Oncos Therapeutics commences clinical study with oncolytic viruses

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors.

Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for ...

Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy

Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers

Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer

Oncolytic-adenovirus-expressed RNA interference for cancer therapy.

Importance of the field: RNA interference (RNAi) has generated considerable excitement for its potential cancer therapeutic applications. Because of the difficulties in delivering a large amount of si...

RNAi suppressor P19 can be broadly exploited for enhanced adenovirus replication and microRNA knockdown experiments.

RNA interference (RNAi) is a key regulator of various biological systems including viral infection. Within a virus life cycle gene products can be modulated by the RNA interference (RNAi) pathway whic...

Oncolytic adenovirus based on serotype 3.

Oncolytic adenoviruses have been safe in clinical trials but the efficacy has been mostly limited. All published trials have been performed with serotype 5 based viruses. The expression level of the A...

Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development.

Oncolytic adenoviruses are a promising treatment alternative for many advanced cancers, including colorectal cancer. However, clinical trials have demonstrated that single-agent therapy in advanced tu...

GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.

The limitations of the current oncolytic adenoviruses for cancer therapy include insufficient potency and poor distribution of the virus throughout the tumor mass. To address these problems, we genera...